Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The price of Repligen Corp. (NASDAQ: RGEN) closed at $160.98 in the last session, down -1.94% from day before closing price of $164.17. In other words, the price has decreased by -$1.94 from its previous closing price. On the day, 0.53 million shares were traded. RGEN stock price reached its highest trading level at $169.2089 during the session, while it also had its lowest trading level at $160.16.
Ratios:
We take a closer look at RGEN’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 11.95 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 119.82. For the most recent quarter (mrq), Quick Ratio is recorded 5.75 and its Current Ratio is at 7.02. In the meantime, Its Debt-to-Equity ratio is 0.36 whereas as Long-Term Debt/Eq ratio is at 0.32.
On July 20, 2023, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $185.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 11 ’24 when KURIYEL RALF sold 3,517 shares for $193.73 per share. The transaction valued at 681,348 led to the insider holds 24,260 shares of the business.
Hunt Anthony sold 16,707 shares of RGEN for $3,298,632 on Mar 08 ’24. The Chief Executive Officer now owns 185,249 shares after completing the transaction at $197.44 per share. On Feb 27 ’24, another insider, DAWES KAREN A, who serves as the Director of the company, sold 1,000 shares for $193.35 each. As a result, the insider received 193,350 and left with 87,367 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RGEN now has a Market Capitalization of 8988881920 and an Enterprise Value of 8938508288. As of this moment, Repligen’s Price-to-Earnings (P/E) ratio for their current fiscal year is 223.37, and their Forward P/E ratio for the next fiscal year is 77.78. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 12.44. For the stock, the TTM Price-to-Sale (P/S) ratio is 14.06 while its Price-to-Book (P/B) ratio in mrq is 4.55. Its current Enterprise Value per Revenue stands at 13.993 whereas that against EBITDA is 71.915.
Stock Price History:
The Beta on a monthly basis for RGEN is 1.03, which has changed by -0.032106757 over the last 52 weeks, in comparison to a change of 0.2160933 over the same period for the S&P500. Over the past 52 weeks, RGEN has reached a high of $211.13, while it has fallen to a 52-week low of $110.45. The 50-Day Moving Average of the stock is -15.68%, while the 200-Day Moving Average is calculated to be -5.19%.
Shares Statistics:
According to the various share statistics, RGEN traded on average about 539.63K shares per day over the past 3-months and 476440 shares per day over the past 10 days. A total of 55.77M shares are outstanding, with a floating share count of 51.97M. Insiders hold about 6.82% of the company’s shares, while institutions hold 104.95% stake in the company. Shares short for RGEN as of 1711584000 were 4770738 with a Short Ratio of 8.84, compared to 1709164800 on 4876287. Therefore, it implies a Short% of Shares Outstanding of 4770738 and a Short% of Float of 10.0.
Earnings Estimates
The market rating for Repligen Corp. (RGEN) is a result of the insights provided by 12 analysts actively involved in the assessment.On average, analysts expect EPS of $0.3 for the current quarter, with a high estimate of $0.34 and a low estimate of $0.27, while EPS last year was $0.64. The consensus estimate for the next quarter is $0.33, with high estimates of $0.37 and low estimates of $0.29.
Analysts are recommending an EPS of between $1.49 and $1.44 for the fiscal current year, implying an average EPS of $1.46. EPS for the following year is $2.07, with 11 analysts recommending between $2.35 and $1.85.
Revenue Estimates
According to 12 analysts, the current quarter’s revenue is expected to be $150.06M. It ranges from a high estimate of $154.64M to a low estimate of $146M. As of the current estimate, Repligen Corp.’s year-ago sales were $182.66M, an estimated decrease of -17.80% from the year-ago figure.
A total of 12 analysts have provided revenue estimates for RGEN’s current fiscal year. The highest revenue estimate was $644.4M, while the lowest revenue estimate was $628M, resulting in an average revenue estimate of $635.62M. In the same quarter a year ago, actual revenue was $638.76M, down -0.50% from the average estimate. Based on 11 analysts’ estimates, the company’s revenue will be $736.53M in the next fiscal year. The high estimate is $772.35M and the low estimate is $718M. The average revenue growth estimate for next year is up 15.90% from the average revenue estimate for this year.
